Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Abstract: During the 48-week treatment period, two patients in the ETV monotherapy group had viral breakthrough and the strains were confirmed to be of a variant associated with ETV resistance (rtM204V+ rtL180M+ rtT184G), while one patient receiving LdT plus ADV had viral breakthrough and an LdT-associated resistance mutation (rtM204I) was detected.
Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients.
Abstract: Anti-HBV drug resistant mutations were detected in 54% (6/11) (i.e., any combination of rtV173L, rtL180M, M204V) and 45% (5/11) had an immune escape mutation (sP120S).
Detection of rtN236T mutation associated with adefovir dipivoxil resistance in Hepatitis B infected patients with YMDD mutations in Tehran.
PMID: 23467016
2013
Iranian journal of microbiology
Result: LAM resistance analysis using RFLP method identified the type of YMDD mutations; 24(80%) patients had the rtM204I mutation, 2 (6.6%) had the rtM204V and 4(13.3%) had both.
Table: M204V
Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.
Result: rtV173L, rtL180M, rtA181V/T, rtT184G, rtS202I, rtM204V/I, rtN236T and Result: Overall, only 1 patient who had never received 3TC or FTC for HBV- or HIV-infection presented M204V and L180M mutations.
Figure: Cumulative selection of 3TC resistant (rtM204V/I) strains over time in patients who ever received 3TC or FTC.
Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis.
PMID: 23557465
2013
Expert opinion on pharmacotherapy
Abstract: The use of entecavir monotherapy in patients with a known rtM204V lamivudine-resistant mutation should be avoided due to increased risk of developing entecavir resistance and failing treatment.
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
Abstract: Complex mutational patterns characterized by the co-presence of rtM204V/I-rtA181T/V (impairing the efficacy of all anti-HBV drugs) were detected in four patients (2.7%) with virological rebound.
Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naive chronic HBV patients.
Abstract: An additional five patients developed entecavir genotypic resistance, with prior occurrence of lamivudine-resistant mutation (L180 M +- M204 V/I).
Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B.
Abstract: In patient 5, M204V/I was detected in 1% and 2% of clones, respectively.
Result: Among six patients with LAM failure, cloning and sequencing data on the RT region of HBV revealed that LAM resistance mutation, L180M or M204V/I substitutions, pre-existed in patient 1, 2, 5, and 6, albeit a small percentage (1% to 2%).
Result: At 6 months of LAM therapy, quasispecies variants bearing LAM resistance mutations, M204V/I+L180M, appeared in all six patients.
Result: At baseline, some colonies contained LAM or ETV resistant mutations such as L80V/I, L180M, M204V/I, A181V, and
HBV mutation literature information.
PMID: 
2013
Journal of viral hepatitis
Browser Board
Co-occurred Entities
Filtrator
ViMRT